Genervon
1055 E. Colorado Boulevard. Fifth Floor
Pasadena
California
91106
United States
Tel: 323-721-5500
Fax: 323-721-9131
Website: http://www.genervon.com/
19 articles about Genervon
-
Genervon Presents Mechanisms of Actions in Alzheimer’s Disease, Including Results Confirming that GM6 Attenuates Alzheimer’s Disease in Mouse Model, in Part by Reducing Inflammation
9/25/2018
Following the closure of several research programs for Alzheimer’s disease, in early 2018 the FDA issued a release entitled “Draft Guidance for Industry: Early Alzheimer’s Disease: Developing Drugs for Treatment.”
-
Genervon Presents Innovative CNS Drug Candidate at 2018 BIO CEO & Investor Conference
2/26/2018
Introduced Genervon’s guiding hypothesis that multi-target drug development is the key to curing complex neurological disorders.
-
Genervon's GM604 Is a Multi-Target Regulator That Provides a Novel Treatment Strategy for ALS
12/8/2017
Genervon is presenting its recent findings at the 28th national symposium on ALS/MND in Boston on Saturday, December 9, 2017.
-
Confidential Data From Genervon ALS Phase IIA Clinical Trial Were Released And Published
3/23/2017
-
Genervon Release: Company Reveals ALS, PD And AD Disease-Associated Gene Lists Modulated By GM6 And Encourages Researchers To Explore New Discoveries Beyond Single Target Drug Development Paradigm
1/10/2017
-
Genervon Release: ALS And Alzheimer’s Disease Bioinformatics Reports Confirm GM6’s Role As Regulator Of Disease-Relevant Pathways
12/27/2016
-
Genervon Release: GM604 To Be Granted "Orphan Drug" Status In Europe
5/3/2016
-
Genervon GM604 Reduced TDP-43 Protein Aggregates And Slowed Down ALS Progression
9/22/2015
-
Genervon Filed Patent For Using GM604 Modulations Of ALS Disease Biomarkers Showing Homeostasis, Leading To Prognosis And Therapeutic Treatment For ALS Disease
6/29/2015
-
FDA, Genervon and ALS Blogger Battle Over Clinical Trial Interpretation
4/22/2015
-
Genervon Announces ALS Compassionate Use Results
1/8/2015
-
Genervon Announces ALS And PD Phase 2a Trial Results
10/20/2014
-
Genervon Announces Biomarker Data From GALS-001 Clinical Trial For ALS
6/30/2014
-
Genervon Successfully Completes Its Phase 2a Clinical Trial For ALS
4/28/2014
-
FDA Grants "Orphan Drug" Designation For Genervon’s Breakthrough Multi-Target ALS Bio-Drug GM604
3/3/2014
-
FDA Granted Fast Track Designation for Genervon's Breakthrough Biotechnology Multi-Target ALS Drug GM604 Expediting Drug Approval Process
6/27/2013
-
Multiple Target ALS Drug Ready for Genervon's Phase 2 Trial
5/21/2013
-
Genervon Will Present at Biotech Showcase Mechanisms of Actions of GM604 on 30 ALS Genes
1/4/2013
-
Genervon Established That Its Targeted Drug Benefits ALS Disorder Through 8 Pathways and Modulates Over 30 Specific ALS Genes Dynamically
12/13/2012